Combined modality adjuvant therapy for high-risk endometrial cancer
Mené sur 660 patientes atteintes d'un cancer de l'endomètre à haut risque de récidive traité entre 2006 et 2013 (âge médian : 62 ans ; durée médiane de suivi : 42,3 mois), cet essai multicentrique international de phase III évalue, du point de vue de la toxicité et de la qualité de vie des patientes, la possibilité d'ajouter une chimiothérapie par cisplatine-carboplatine-paclitaxel à une radiothérapie adjuvante
The incidence of endometrial cancer has steadily increased over the past decade, with 320 000 new cases reported worldwide in 2012.1 Endometrial cancer is the fifth most common cancer in women, and incidence is projected to increase2 because of an increased prevalence of obesity and an ageing population. Although most patients present with early-stage low-risk disease, a rise in incidence is expected to lead to an increasing number of high-risk cases at presentation. This heterogenous group of tumours is characterised by higher grade and stage, deep myometrial invasion, lymph-vascular space invasion, or non-endometrioid histologies, such as serous or clear-cell cancers.
The Lancet Oncology , commentaire, 2015